Dana-Farber Cancer Institute | Strategic Alliance Partners

August 03, 2023

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

August 01, 2023

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.

July 31, 2023

Maxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.

July 31, 2023

Researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas– incurable brain tumors– can arise due to changes in the epigenome.

July 31, 2023

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

July 31, 2023

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

July 28, 2023

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.

July 27, 2023

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

July 27, 2023

Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.

July 27, 2023

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

July 27, 2023

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

July 26, 2023

Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.

July 25, 2023

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

July 25, 2023

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

July 25, 2023

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

July 24, 2023

Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.

July 24, 2023

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

July 24, 2023

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

July 24, 2023

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

July 20, 2023

Nikhil C. Munshi, MD, discusses the implications of the findings from the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and the CAR T-cell therapy’s subsequent FDA approval for use in this patient population.